• FDA approves bexagliflozin for adults with type 2 diabetes

    1 day ago - By Healio

    The FDA approved bexagliflozin, an oral SGLT2 inhibitor, to improve glycemic control for adults with type 2 diabetes, according to a company press release.
    The approval of bexagliflozin is based on results from 23 clinical trials evaluating the safety and efficacy of bexagliflozin with more than 5,000 adults with type 2 diabetes. These trials demonstrated a significant reduction in HbA1c and fasting blood glucose with bexagliflozin treatment after 24 weeks. This treatment can be utilized as a monotherapy or combined with metformin or as an add-on to standard-of-care
    Read more ...